Oxcarbazepine Tablet, Film Coated
Product Images NDC 50268-679

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 50268-679). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avpak, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

50 (679 15)

Label for Oxcarbazepine Tablets, USP 150 mg film-coated tablets, oral route, packaged as 50 tablets (5 x 10) unit dose. The label shows NDC 50268-679-15 and notes Rx Only. It includes storage instructions, pharmacist dispensing guidance, manufacturer information (AvPAK, Pulaski, TN), and a barcode.*

FDA Label Image

50 (680 15)

Label for Oxcarbazepine Tablets, USP 300 mg, film coated oral tablets. The label indicates a unit dose package containing 50 tablets (5 x 10). It is prescription only and manufactured for AvPAK. Storage instructions and pharmacist dispensing guidance are included. Barcode and QR code are also visible.*

FDA Label Image

50 (681 15)

Oxcarbazepine Tablets USP 600 mg film-coated oral tablets, packaged as 50 tablets (5 x 10 unit doses). The label indicates prescription use only. Manufactured for AvPAK, the label includes storage instructions and a barcode with NDC 50268-681-15.*

FDA Label Image

Oxcarbazepinetabfig1 (Oxcarbazepinetabfig1)

A Kaplan-Meier survival curve chart comparing exit rates over time on a trial for Oxcarbazepine versus placebo. The horizontal axis represents time on trial from Day 2 to Day 11 (in days), and the vertical axis represents the exit rate from 0 to 1. Oxcarbazepine is shown as a solid line with a lower exit rate, and placebo as a dashed line with a higher exit rate. A log-rank test p-value of 0.0001 is displayed.*

FDA Label Image

Oxcarbazepinetabfig2 (Oxcarbazepinetabfig2)

A Kaplan-Meier survival curve graph depicting seizure rate over days from the first dose to first seizure. The graph compares treatment groups: Oxcarbazepine (solid line) and Placebo (dashed line), showing a difference in seizure rates with a log-rank test p-value of 0.046.*

FDA Label Image

Oxcarbazepinetabfig3 (Oxcarbazepinetabfig3)

A Kaplan-Meier plot showing exit rate over time in days for two treatment groups labeled as HIGH and LOW. The solid line represents the HIGH group, and the dotted line represents the LOW group, with a log-rank test p-value of 0.0001 indicating statistical comparison between the groups.*

FDA Label Image

Oxcarbazepinetabfig4 (Oxcarbazepinetabfig4)

A Kaplan-Meier survival curve chart showing exit rate over time (days) for two treatment groups labeled as HIGH and LOW. The x-axis represents time to exit in days, ranging from 0 to 130, and the y-axis represents the exit rate from 0.0 to 1.0. The LOW group (dashed line) shows a higher exit rate over time compared to the HIGH group (solid line). A log-rank test p-value of 0.0001 is displayed on the chart.*

FDA Label Image

Oxcarbazepinetabstruct (Oxcarbazepinetabstruct)

Chemical structure of Oxcarbazepine, showing its molecular framework with key rings and functional groups including a ketone and an amide moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.